سعر امريزول 125مجم/5مل معلق 120 مل 2024

Metronidazole 125 mg/5 ml oral suspension in a 120 ml bottle (Amrizole, Amriya, Egypt), a nitroimidazole antiprotozoal/antibacterial.

• Symptomatic and asymptomatic trichomoniasis (T. vaginalis) in females and males, including treatment of sexual partners.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Acute intestinal amoebiasis (amoebic dysentery) and amoebic liver abscess.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Serious infections caused by susceptible anaerobic bacteria (intra-abdominal, skin and skin structure, gynaecological, bacterial septicaemia, bone and joint, CNS, lower respiratory tract infections and endocarditis).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common: nausea, headache, anorexia, metallic taste, vomiting, diarrhoea, epigastric distress and abdominal cramping; darkened urine may occur.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to metronidazole or other nitroimidazole derivatives.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Use of disulfiram within the last 2 weeks (psychotic reactions).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Consumption of alcohol or products containing propylene glycol during therapy and for at least 3 days afterwards (disulfiram-like reaction).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metronidazole has been carcinogenic in mice and rats; unnecessary use should be avoided and use reserved for approved indications.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP) have been reported; discontinue at the first sign of rash.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Central and peripheral nervous system effects: encephalopathy, peripheral and optic neuropathy, convulsive seizures and aseptic meningitis; stop treatment if abnormal neurological signs appear.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Alcohol and propylene glycolDisulfiram-like reaction (abdominal cramps, nausea, vomiting, headache, flushing); avoid during and for 3 days after therapy.DailyMed (U.S. National Library of Medicine)
• DisulfiramPsychotic reactions; do not give metronidazole within 2 weeks of disulfiram.DailyMed (U.S. National Library of Medicine)
• Warfarin and other oral coumarin anticoagulantsPotentiates anticoagulant effect (prolonged prothrombin time/INR); monitor and adjust.DailyMed (U.S. National Library of Medicine)

• Older-format US label: no adequate and well-controlled studies in pregnant women; published data covering more than 5,000 exposed pregnancies (many in the first trimester) - one study suggested an increased risk of cleft lip, not confirmed by others. Metronidazole crosses the placenta; contraindicated in the first trimester for trichomoniasis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Metronidazole is present in human milk at concentrations similar to maternal serum; a nursing mother may pump and discard milk during therapy and for 48 hours after the last dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Metronidazole: After passive diffusion into susceptible anaerobes it is reduced intracellularly (via electron-transport proteins such as ferredoxin) to a short-lived nitroso free radical; the reduced drug and free radicals can interact with DNA, inhibiting DNA synthesis and causing DNA degradation and bacterial death; the precise mechanism is unclear (US label).